SPOTLIGHT ON INDUSTRY: Richard Alldread, Head of Innovation, CPI Biologics
Richard Alldread, Head of Innovation, CPI Biologics
What is your background and current job role?
My background is in protein engineering and recombinant protein expression. Initially with a view to understanding the nature of thermostability in enzymes from thermophilic bacteria. From there I developed prokaryotic and eukaryotic recombinant expression systems for a variety of uses (drug discovery, diagnostics, biotherapeutics). For the last 10 years or so my focus has been predominantly on the development and manufacture of biotherapeutics.
My current role at CPI is Head of Innovation, this role focuses on scouting for and developing new technologies that can be applied to biotherapeutic product development and manufacture, a key part of this is the formation of strong links with the rest of the biotherapeutic research community.
What Industrial Biotechnology and Bioenergy (IBBE) related project is currently being undertaken by your organisation?
CPI Biologics currently have a number of ongoing projects that are relevant, these include:
- Manufacturing methods for a nanoparticle drug delivery system
- In process formulation of biotherapeutics
- Engineering CHO cells for improved process performance
- Improved and streamlined biotherapeutic development pathways
There are numerous other projects currently in the planning stages.
What do you think the challenges related to this project are in the next 1-5 years?
The biotherapeutic industry will face many varied challenges in the next few years, particularly it will need to adapt to the needs of stratified medicine and adopt more efficient and cost effective ways of selecting, developing and manufacturing therapeutic products. There is likely to be an increase in the diversity of therapeutic products (new protein formats, viral vectors for gene therapy, cell therapy) and these will all challenge our current manufacturing operations.
How can other CBMNet members help you and your organisation with your research?
We now have a wide range of technologies available that together have the potential to revolutionise the development and manufacture of biopharmaceuticals (genomics, synthetic biology, microfluidics, 3D printing, cell free expression), some of these are beyond the traditional remit of biotechnologists. Networks such as CBMNet can help by developing a cross disciplinary approach to solving biological problems and ensuring that biotechnologists have access to and an ongoing dialogue with experts from other fields.
You can contact Richard by emailing him at Richard.Alldread@uk-cpi.com